Weighing The Extraordinary Benefits And Disturbing Risks Of The New Weight Loss Drugs | Johann Hari

Jun 12, 2024 Episode Page ↗
Overview

Journalist and best-selling author Johann Hari discusses his new book, "Magic Pill," exploring the extraordinary benefits and disturbing risks of new weight-loss drugs like Ozempic. He shares his personal experience and the complex societal choices we face.

At a Glance
12 Insights
1h 9m Duration
17 Topics
4 Concepts

Deep Dive Analysis

Introduction to GLP-1 Weight Loss Drugs and Personal Conflict

Johann Hari's Personal Journey to Taking Ozempic

Body Positivity, Anti-Fat Bias, and Shelly Bovey's Story

Separating Stigma from the Physical Harms of Obesity

The Root Causes of the Modern Obesity Crisis: Ultra-Processed Food

The 'Cheesecake Park' Experiment and Undermined Satiety

The Dilemma of Artificial Solutions to Artificial Problems

Weighing the Risks and Benefits of GLP-1 Drugs

Potential Side Effects: Thyroid Cancer and Suicidality Concerns

Disrupted Eating Patterns and Surfacing Psychological Issues

Johann Hari's Decision to Continue Ozempic and the Bariatric Surgery Analogy

The Role of Vanity and Societal Judgment in Weight Loss

Five Potential Future Scenarios for GLP-1 Drugs

Societal Choices and Recommendations for GLP-1 Use

Addressing the 'Diet and Exercise' Argument and the Science of Weight Regain

The Biopsychosocial Model of Obesity and Willpower

Responding to Criticism and the Importance of Candor

GLP-1s (Glucagon-Like Peptide-1s)

A new class of weight loss drugs, such as Ozempic, that primarily work on the brain to restore a sense of satiety. These drugs also stimulate insulin creation, which is why they were initially used for diabetes.

Satiety

The feeling of being full and satisfied after eating. This natural signal is often undermined by the consumption of ultra-processed foods, leading to overeating, and GLP-1 drugs aim to restore it.

Biopsychosocial Model of Obesity

A framework explaining obesity as a result of complex interactions between biological factors (genetics, brain changes), psychological factors (comfort eating, willpower), and social factors (food industry, environment).

Weight Regain Mechanism

The body's biological response to weight loss, where the brain actively fights to maintain a higher weight. This involves slowing metabolism, increasing cravings for sugary and fatty foods, and causing lethargy, making sustained weight loss through traditional dieting difficult for most.

?
What are GLP-1 drugs and how do they work?

GLP-1s like Ozempic are new weight loss drugs that primarily work on the brain to give back a sense of satiety, counteracting the undermining effect of ultra-processed foods on our ability to know when to stop eating.

?
What are the potential risks of GLP-1 drugs?

Known side effects include nausea. More serious potential risks, though disputed, include an increased risk of thyroid cancer (50-75% increase in risk, not overall chance) and a possible link to depression or suicidality, which is currently contested.

?
What are the potential benefits of GLP-1 drugs?

For individuals with obesity, these drugs can lead to significant weight loss and health improvements, similar to bariatric surgery, reducing the risk of heart attack, stroke, cancer, and diabetes-related causes.

?
Why is it so hard for most people to lose weight through diet and exercise alone?

The human brain, evolved in times of famine, actively fights weight loss by slowing metabolism, increasing cravings for high-calorie foods, and making individuals more lethargic, making long-term weight maintenance through willpower alone extremely difficult for the vast majority.

?
What caused the current obesity crisis?

The crisis is primarily linked to the transformation of the food supply system from whole, fresh foods to processed and ultra-processed foods, which profoundly undermine our natural satiety signals.

?
Should everyone take GLP-1 drugs for weight loss?

No. For those with a BMI lower than 27, the risks outweigh the benefits. For those with a BMI higher than 35 (and no contraindications like thyroid cancer history or pregnancy), the benefits often outweigh the risks. For BMIs between 27 and 35, the decision is complex and highly individualized, requiring careful consideration of risks and benefits.

?
How do GLP-1 drugs affect comfort eating?

These drugs radically disrupt eating patterns, making it physically difficult to overeat without discomfort or vomiting, which can bring to the surface underlying psychological reasons for comfort eating.

1. Understand Dieting’s Biological Challenges

Recognize that traditional diets often fail for the majority because the brain actively fights weight loss by slowing metabolism, increasing cravings, and reducing energy, a biological response evolved to protect against famine. Relying solely on willpower is often insufficient against these powerful, ingrained mechanisms.

2. Evaluate GLP-1 Use by BMI

If your BMI is below 27, definitely avoid GLP-1 drugs as the risks outweigh the benefits; if your BMI is higher than 35, consider taking them due to the significant risks of obesity at that level, provided you don’t have thyroid cancer in your family, are not trying to get pregnant, and don’t have a history of eating disorders. For BMIs between 27 and 35, a thorough personal assessment of all risks and benefits, as detailed in the book, is necessary.

3. Separate Weight Stigma from Health

Distinguish between the horrific harm caused by societal stigma against overweight individuals and the separate physical health risks associated with obesity. Approach both issues with compassion and love, working to reduce both the stigma and the physical effects, while understanding that obesity is not a personal fault.

4. Recognize Obesity’s Systemic Roots

Understand that the modern obesity crisis is primarily driven by changes in the food supply system, specifically the proliferation of processed and ultra-processed foods that undermine natural satiety signals. This perspective shifts the understanding of obesity away from individual ‘greed’ or ’laziness’ towards environmental factors.

5. Balance Immediate & Systemic Solutions

When facing an immediate health crisis like obesity, address the problem with available solutions (such as GLP-1 drugs) to ’live to fight another day,’ even while simultaneously advocating for and working towards systemic changes (like reforming the food industry) to prevent future problems.

6. Personalize GLP-1 Risk Assessment

Make an individualized decision about GLP-1 use by carefully weighing your personal health risks (e.g., family history of heart disease) against the potential drug risks, ensuring you don’t fall into high-risk categories for side effects like thyroid cancer or eating disorders. This complex, difficult, and individualized question requires a thorough review of evidence.

7. Reframe ‘Cheating’ with GLP-1s

Dispel feelings of ‘cheating’ when using weight loss drugs by moving beyond the idea of gluttony as a sin and recognizing that the true contest is against the forces that caused the obesity crisis, such as the food industry. Foster compassion and understanding rather than shame and anger to navigate this emotional issue.

8. Advocate for GLP-1 Affordability

Support policies that regulate pharmaceutical companies to lower the price of GLP-1 drugs, ensuring they are accessible and affordable for everyone who needs them, rather than being restricted to a small number of rich people. This would address the current ‘scandalous’ situation of unequal access.

9. Strive for Societal Obesity Awakening

Work towards a future where GLP-1 drugs are widely available and effective, but also use this moment to spark a societal awakening to address the underlying structural problems that caused the obesity crisis. The goal is to ensure the next generation doesn’t have to face the ’lousy choice’ between obesity and risky drug options.

10. Practice Candor in Difficult Discussions

Approach controversial and emotionally charged topics with honesty and transparency, acknowledging complexity and relying on facts. This candor can be profoundly de-stigmatizing and lead to healthier physical and psychological outcomes, as ’the antidote to shame is candor’.

11. Utilize 10% Happier Meditation App

Download the new ‘10% with Dan Harris’ app to easily access a library of guided meditations to help with stress, anxiety, sleep, focus, and self-compassion. The app also offers weekly live Zoom community sessions for meditation and Q&A.

12. Subscribe to Dan Harris’s Newsletter

Sign up for Dan Harris’s new newsletter to receive the biggest takeaway from each weekly podcast episode directly to your inbox.

What kind of body positivity is it if it doesn't keep my body alive?

Shelly Bovey

If your house is on fire, it's a very good argument to say, you know, we should build houses with less flammable materials and we should change the building code. So buildings have to have sprinklers. But when your house is on fire, that's no use to you. Call the fire brigade and douse the house with water, right?

Johann Hari (quoting his friend)

These drugs are an artificial solution to an artificial problem.

Professor Michael Lowe

You're not a candidate for taking these drugs, but this is going to transform the society around you in all sorts of complicated ways.

Emily Field (Barclays analyst, as quoted by Johann Hari)

The antidote to shame is candor.

Maggie Nelson (as quoted by Johann Hari)

Johann Hari's Personal Recommendations for GLP-1 Use

Johann Hari
  1. If your BMI is lower than 27, definitely do not take the drugs, as you incur risks for none of the benefits and risk losing muscle mass.
  2. If your BMI is higher than 35, my advice is to take them, provided you don't have thyroid cancer in your family, are not trying to get pregnant, and do not have a history of eating disorders, because the risks of obesity at that level are very great.
  3. If your BMI is between 27 and 35, go through the risks and benefits in the book and wider evidence, as the decision is complex and highly individualized.
More than doubled
Obesity increase in the US Between 1979 and 2000
Doubled again
Severe obesity increase in the US Between 2000 and 2020
78%
Average American child's daily calories from ultra-processed food Percentage of total calories
50% to 75%
Increased thyroid cancer risk with GLP-1s (disputed) Increase in existing risk, not overall chance of getting cancer
1.2%
Lifetime chance of getting thyroid cancer Approximate percentage of people
84%
Thyroid cancer survival rate Percentage of people who survive it
56% less likely
Reduced death from heart attack after bariatric surgery Over 7 years for very obese individuals
60% less likely
Reduced death from cancer after bariatric surgery Over 7 years for very obese individuals
92% less likely
Reduced death from diabetes-related causes after bariatric surgery Over 7 years for very obese individuals
40% less likely
Reduced death from any cause after bariatric surgery Overall reduction in mortality
20% reduction
Reduced risk of heart attack or stroke with Wegovy/Ozempic If starting with a BMI higher than 27 over the next few years
About $40 a month
Cost to manufacture GLP-1 drugs Excluding pharmaceutical company profits
2032
Ozempic patent expiration Expected year, leading to potential generic availability
2 pounds
Average weight loss after 2 years on a diet Based on studies following people over longer time periods
70%
Americans who are overweight or obese Percentage of the US population
45%
Women with BMI higher than 35 insulted daily Percentage of women in this category
1 in 7
Breast cancer incidence in British women Rate of occurrence
1 in 8
Breast cancer incidence in American women Rate of occurrence
1 in 38
Breast cancer incidence in Japanese women Rate of occurrence
15 years
Years knocked off life by diabetes On average, as one of many effects of the condition
More than 17
New weight loss drugs in development based on GLP-1 mechanisms Currently in various stages of development
37
Gut hormones known to reduce appetite Number identified by scientists
18 million
Fen-Fen prescriptions in 1995 Number of prescriptions for the diet drug
$12 billion
Fen-Fen pharmaceutical payout Largest payout in pharmaceutical industry history at that point due to side effects